# Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Study · id `cardio:ct-nct02348723` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02348723](<https://clinicaltrials.gov/study/NCT02348723>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02348723

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 678 participants.

## Technical summary

Registry record NCT02348723. Randomized; no masking; primary purpose treatment. Start 2015-04-28 (actual); primary completion 2016-11-11 (actual). Results posted on 2017-11-14.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 678 participants (enrolled count; ClinicalTrials.gov record NCT02348723, source copy `cardio:ctgov-nct02348723-2018-01-29`, retrieved 2026-10-26)
- Started: 2015-04-28 (actual) (ClinicalTrials.gov record NCT02348723, source copy `cardio:ctgov-nct02348723-2018-01-29`, retrieved 2026-10-26)
- Primary completion: 2016-11-11 (actual) (ClinicalTrials.gov record NCT02348723, source copy `cardio:ctgov-nct02348723-2018-01-29`, retrieved 2026-10-26)
- Completion: 2016-11-14 (actual) (ClinicalTrials.gov record NCT02348723, source copy `cardio:ctgov-nct02348723-2018-01-29`, retrieved 2026-10-26)
- Results first posted: 2017-11-14 (ClinicalTrials.gov record NCT02348723, source copy `cardio:ctgov-nct02348723-2018-01-29`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; France; Germany; Italy; Japan; Netherlands; Russia; Spain; United Kingdom (ClinicalTrials.gov record NCT02348723, source copy `cardio:ctgov-nct02348723-2018-01-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02348723-2018-01-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)
- Condition: Atrial Fibrillation
- Intervention (Drug): Warfarin
- Intervention (Drug): Dabigatran Etexilate 150mg
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation (`cardio:pubmed-28317415`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study (`cardio:pubmed-30758702`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d300b625603a3b2d9ee2778ea6252f6b6dc90c52cc15d42c7708a1aeeb3c25d1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
